Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) announced its participation in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference. Management will engage in a fireside chat presentation on Thursday, Sept. 26, 2024 at 9:20 a.m. EDT. A live webcast will be available on the company's website under the Investors tab and archived for 14 days.

Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. Their portfolio includes proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company also has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes has additional facilities in Massachusetts and Ohio.

News Market Reaction – ALKS

+0.71%

+0.71% Session move

In the trading session that priced this news, ALKS gained 0.71%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DUBLIN, Sept. 19, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the TD Cowen 4^th Annual Novel Mechanisms in Neuropsychiatry Conference on Thursday, Sept. 26, 2024 at 9:20 a.m. EDT (2:20 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-the-td-cowen-4th-annual-novel-mechanisms-in-neuropsychiatry-conference-302253314.html

SOURCE Alkermes plc

FAQ

When is Alkermes (ALKS) participating in the TD Cowen Neuropsychiatry Conference?

Alkermes (ALKS) is participating in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference on Thursday, September 26, 2024 at 9:20 a.m. EDT.

What type of presentation will Alkermes (ALKS) give at the conference?

Alkermes (ALKS) management will participate in a fireside chat presentation at the conference.

Where can investors access the live webcast of Alkermes' (ALKS) presentation?

Investors can access the live webcast of Alkermes' (ALKS) presentation under the Investors tab on www.alkermes.com.

How long will the webcast of Alkermes' (ALKS) presentation be archived?

The webcast of Alkermes' (ALKS) presentation will be archived for 14 days.

What are the main therapeutic areas Alkermes (ALKS) focuses on?

Alkermes (ALKS) focuses on developing innovative medicines in neuroscience, with products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder.